Hyperphosphatemia Clinical Trial
Official title:
The Effect of Low-Phosphate Diet on Fibroblast Growth Factor-23 Level in Patients Undergoing Hemodialysis
The aims of the study are to evaluate the effect of low-phosphate diet on FGF23 level and to determine the optimal amount of dietary phosphate restriction in hemodialysis patients. In particular, the investigators will assess the comparing effect of pre-specified low-phosphate diets, very low-phosphate diet, phosphate-to-protein ratio (PPR) value of 8 mg/g, versus low-phosphate diet, PPR value of 10 mg/g, on the change of FGF23 and phosphate level.
In patients with hemodialysis, the prevalence of cardiovascular disease (CVD) is high, and is
the leading cause of death. Among several cardiovascular risk factors of hemodialysis
patients, elevated fibroblast growth factor-23 (FGF23) level is common, and plays major role
in the development of CVD with independent pathophysiologic mechanisms. Evidence from animal
studies demonstrated that low-phosphate diet reduced FGF23 level. Clinical trials assessing
the effect of dietary phosphate restriction on FGF23 focused on non-dialysis populution.
However, little is known about the effect of low-phosphate diet on FGF23 in hemodialysis
patients who have higher prevalence of hyperphosphatemia and severely elevated FGF23 level.
In addition, current clinical guideline, based on evidence from observational studies of
non-dialysis population, has recommended that dietary phosphate intake should be restricted
to 800-1000 mg/day (adjusted for dietary protein needs) when serum phosphate levels are
greater than 5.5 mg/dL in those with kidney failure. For hemodialysis population, the optimal
amount of dietary phosphate restriction has not been determined. The aims of the study are to
evaluate the effect of low-phosphate diet on FGF23 level and to determine the optimal amount
of dietary phosphate restriction in hemodialysis patients. In particular, the investigators
will compare the effect of pre-specified low-phosphate diets, very low-phosphate diet,
phosphate-to-protein ratio (PPR) value of 8 mg/g, versus low-phosphate diet, PPR value of 10
mg/g, on the change of FGF23 and phosphate level.
It is to conduct a randomized, active-controlled trial with cross-over design at a
hemodialysis unit of tertiary teaching hospital in Northern Taiwan. Subjects with aged older
than 20 years, end-stage renal disease undergoing thrice-weekly hemodialysis for more than
three months, having adequate dialysis (urea reduction ratio equal to or greater than 65%)
and the most recent serum phosphate level greater than 5.5 mg/dL or between 3.5 and 5.5 mg/dL
with regular phosphate binder use will be randomly assigned into two groups: those in group A
will receive 2-day diet with known PPR of 8 mg/g, followed by 5-day washout period and then
receive another 2-day diet with PPR of 10 mg/g. The opposite order of diets will be
prescribed in group B. The study diets will be prepared and cooked at hospital cafeteria.
Dietary compositions of the study diets were analyzed before the start of the study. Primary
outcome measures are difference in change-from-baseline intact FGF-23 level between the two
dietary interventions. Secondary outcomes include changes in serum phosphate, intact
parathyroid hormone and C-terminal FGF-23 level.
Since food additives include readily absorbable inorganic phosphorus, only natural food
sources were chosen for study diets. All study food items had the following unique
characteristics including: 1. Using locally produced raw materials. 2. Meeting healthy and
safety requirements. 3. Complying with national quality standards. Prior to enrollment of the
eligible patients, the study diets were prepared and cooked with the food hygiene practice
using Hazard Analysis and Critical Control Points (HACCP) system at hospital cafeteria and
dietary composition of study diets were analyzed for chemical analysis. With reference to
Association of Official Analytical Communities (AOAC) Official Method 984.27, phosphorus, and
calcium were determined by inductively coupled plasma-optical emission spectrometer (ICP-OES)
analysis with the detection limit of 0.1 mg/L. In brief, the sample weight were obtained, the
edible portions of samples were ashed at high temperature, digested in nitric acid, and used
inductively coupled plasma to determine their actual contents of phosphorus and calcium. With
reference to Taiwanese official methods, study diets were measured for analyses of protein,
fat, saturated fat, sugar, moisture, and ash. Carbohydrates were calculated by the formula:
100 - (Protein + Fat + Moisture + Ash) (g/100 g). Calories were calculated by the formula:
Protein (g) x 4 kcal + Fat (g) x 9 kcal + Carbohydrate (g) x 4 kcal.
Based on the measured values of food items, dietitian had crafted low-phosphate diets. Less
than 800 mg per day of phosphate amount is designed to fulfill the current clinical
recommendation. Two different contents of phosphate diets were prepared to find out the
optimal amount of dietary phosphate. Each of the diets was designed to have similar calcium,
protein and total caloric contents but only differ in phosphate contents. To enhance
nutrition, and to reduce phosphate amount and bioavailability, study diets were designed to
fulfill the following criteria including high protein diet (≧1.2 g/kg/day), adequate calories
(≧ 30 kcal/kg/day), low phosphate-to-protein ratio (< 10 mg/g), and higher percentage of
plant source of phosphate than that of animal source. In addition, meats were sliced and
boiled for 30 minutes before cooking to reduce the amount of phosphate while preserving
protein content.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
Completed |
NCT01252771 -
Phosphate Kinetic Modeling 2
|
Phase 4 | |
Completed |
NCT01187628 -
Long-term Study in Chronic Kidney Disease (Extension From Study 14817)
|
Phase 3 | |
Unknown status |
NCT01245517 -
The Influence of Dietary Phosphorus Education Program on Nutritional Status and Serum Phosphate Level Among Hemodialysis Patient
|
N/A | |
Completed |
NCT00506441 -
A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
|
Phase 3 | |
Recruiting |
NCT04440696 -
To Evaluate the Patient Tolerance, Pharmacodynamics and Pharmacokinetics of Lanthanum Polystyrene Sulfonate Powder
|
Phase 1/Phase 2 | |
Completed |
NCT01976572 -
Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01742585 -
A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis
|
Phase 3 | |
Completed |
NCT01191255 -
A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis
|
Phase 3 | |
Completed |
NCT01003223 -
Phosphate Kinetic Modeling
|
N/A | |
Completed |
NCT00505037 -
A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis
|
Phase 2 | |
Completed |
NCT00508885 -
The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04551300 -
A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients
|
Phase 2 | |
Completed |
NCT01955876 -
Fosrenol Post-marketing Surveillance in Japan
|
N/A | |
Completed |
NCT04579315 -
Long-term Effects of the New Nordic Renal Diet in Patients With Moderate Chronic Kidney Disease
|
N/A | |
Completed |
NCT03861247 -
Individualized Treatment of Hyperphosphatemia in Maintenance Hemodialysis Patients
|
Phase 3 | |
Terminated |
NCT01725113 -
Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol
|
Phase 4 | |
Recruiting |
NCT01238588 -
The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan
|
N/A | |
Completed |
NCT00542815 -
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
|
Phase 3 | |
Completed |
NCT04549597 -
Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia
|
Phase 4 |